CI Cigna Group Insider Trading

Cordani sells 201.9K CI shares for $59.1M under pre-arranged 10b5-1 plan; retains 57.8K shares

David Cordani, Chairman & CEO of Cigna Group, executed 13 sales totaling 201,878 shares for $59,114,186.29 on May 12, 2026, pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-02-06—making this a scheduled, non-discretionary transaction rather than a signal of conviction or concern. While Cordani's prior 19 sell transactions across all tickers achieved an 88.89% well-timed rate at the 90-day mark, the recent stock performance context matters: CI is trading at $294.93, down 13.0% from its 52-week high of $338.89, though up 8.2% over the past 30 days and 1.2% over 90 days. Post-transaction, Cordani retains 57,766 shares, demonstrating continued skin-in-the-game, and Cigna's fundamentals remain solid with $68.5B in annual revenue, $1.7B net income, 11.2% YoY revenue growth, and a 12.41 P/E ratio. The pre-arranged plan status limits the signaling power of this sale for inferring current insider sentiment.

Cigna CEO Cordani buys 4,134 shares for $999.9K; stock down 24.6% from 52-week high, holdings rise 2.7%

David Cordani, Chair & CEO of Cigna Group, purchased 4,134 shares at $241.88 on 2025-11-03 for a total value of $999,916.21, increasing his holdings from 153,801 to 157,935 shares (+2.7%). The purchase occurred while the stock trades at $258.62, down 24.6% from its 52-week high of $343.06 and down 16.8% over the past 30 days. Cordani's prior sell activity at this ticker shows strong timing discipline: 4 of 5 prior CI sales resulted in negative 90-day returns, indicating he consistently sold before declines. His cross-ticker track record reflects a 88.89% well-timed sell rate, suggesting consistent pattern recognition in market conditions. Against this backdrop, this open-market purchase during a significant drawdown warrants investor attention as a signal from a history-proven trader, though it should be evaluated alongside the company's fundamentals: Cigna reported $69.7B in latest-quarter revenue, $2.0B net income, 26.6% annual revenue growth, and a P/E of 10.55, indicating a mature, profitable business trading at reasonable valuation.

Cigna Group exec Brian C Evanko sold 5,368 shares at $300.00 (-9.3% of holdings); stock now $307.14, down 14.4% from 52-week high.

Brian C Evanko sold 5,368 shares of CI at $300.00 on 2025-10-03, reducing his holdings from 57,451 to 52,083 shares. The sale occurred below the current price of $307.14 and well below the 52-week high of $358.58, suggesting the exit was timed before recent momentum rather than at a peak. Evanko's cross-ticker track record shows 2 prior open-market sells with an average 90-day return of +3.2% (poorly timed; stock rose after) and a 90d well-timed rate of 0.00%, indicating a history of selling before rallies rather than declines. At this same ticker (CI), his prior 2 trades also show mixed outcomes: a June 2024 sell followed by a +3.2% 90-day return, consistent with the cross-ticker pattern. The sale represents a modest 9.3% reduction in a large remaining position at a company with strong fundamentals (Revenue $67.2B, Net income $1.6B, Annual growth +26.6%, P/E 15.17).

Nicole S Jones sells 28,526 CI shares at $300.00 for $8,557,800; cuts holdings by 50.2% to 28,325 shares

Nicole S Jones executed a substantial open-market sale of 28,526 shares at $300.00 on 2025-08-15, reducing her Cigna Group holdings by exactly 50.2% from 56,851 to 28,325 shares. The transaction occurred at a price -17.6% below the 52-week high of $366.85, and the stock has risen 2.2% over the prior 30 days and fallen 4.7% over the prior 90 days. Jones's cross-ticker track record shows 4 prior sells with a 90-day well-timed rate of 33.33%, while her same-ticker history at CI spans 4 prior sales with only 1 of 3 measurable outcomes showing a negative 90-day return. The fundamental backdrop shows Cigna with strong revenue growth of 26.6% annually, a trailing P/E of 14.93, and a market cap of $80,641,640,738.25. Investors should note the magnitude of the position reduction and compare it against the company's stable valuation metrics and revenue expansion trajectory.

Cigna exec Eder Noelle K sells 9,944 CI shares at $320.00 for $3.2M, reducing stake by 42.6% to 13.4K shares held.

Eder Noelle K sold 9,944 shares of Cigna Group (CI) at $320.00 on 2025-03-07, reducing her post-transaction holdings to 13,406 shares from 23,350 shares, representing a 42.6% reduction in position. The sale occurred at a price $2.13 above the current market price of $317.87, and the stock is currently -13.4% below its 52-week high. Her prior open-market sell activity shows a 100.00% well-timed rate at the 90-day mark, though she has only 1 prior sell on record. The company's fundamentals include revenue of $63,694,000,000.00, net income of $825,000,000.00, and a P/E of 49.59, indicating elevated valuation multiples. Without disclosure of the underlying motivation or any scheduled trading plan, the significance of this transaction remains moderate—it is neither immaterial nor conclusively indicative of a material shift in conviction, and the sale's timing relative to broader market context does not yet constitute material new information by itself.

Cordani sold 26,527 CI shares at $308.12 for $8.2M; down -17.2% from prior holdings. 5 of 5 prior CI sales were well-timed.

David Cordani, Chairman & CEO, sold 26,527 shares of Cigna Group on 2025-03-03 at $308.12, reducing his holdings to 127,767 shares. His entire 5-trade history at this ticker shows well-timed sales: each prior CI sale resulted in negative 90-day returns ranging from -2.2% to -5.7%, indicating the stock declined after each sale. His cross-ticker track record reinforces this pattern with a 94.12% well-timed rate across 20 prior sells averaging -3.0% 90-day return. The current price of $308.86 is -15.8% from the 52-week high of $366.85, and Cigna trades at a P/E of 48.18 on $63.7B in quarterly revenue and positive 26.6% annual revenue growth. The sale is modest in absolute terms ($8.2M) against a $84.5B market cap, yet the consistent pattern of well-timed selling at this ticker warrants monitoring for any signal about insider conviction at current valuations.

Nicole S Jones sold 4,904 shares of Cigna (CI) at $308.12; retains 29,421 shares post-transaction

Nicole S Jones executed a sale of 4,904 shares at $308.12, reducing her holdings by 14.3% to 29,421 shares. The current price of $308.86 is -15.8% from the 52-week high, and the stock has posted a 30-day change of +5.0% and a 90-day change of -6.4%. Across her cross-ticker track record, Jones' prior 3 open-market sells showed a 90-day well-timed rate of 50.00%, though her same-ticker history at CI presents mixed outcomes: 1 of her 2 prior measurable CI sells at the 90-day mark was well-timed. The sale occurs against a backdrop of Cigna's strong revenue growth of +26.6% year-over-year and solid fundamentals ($63.7B in latest quarterly revenue, $825.0M net income), though the P/E of 48.18 reflects a rich valuation relative to near-term earnings.

Jones Nicole S sold 22,030 shares of CI at $330.96 for $7,291,048.80 on 2024-08-12; stock now $334.90.

Jones Nicole S sold 22.0K shares (44.7% reduction in holdings) on 2024-08-12, reducing her position from 49.3K to 27.2K shares. The sale occurred at $330.96, and the stock has since moved to $334.90 (within the 52-week range of $257.49–$364.08). Examining her prior trades at Cigna, both previous sells on 2024-03-04 and 2023-08-21 showed positive 90-day returns (+3.6% and +2.1% respectively), indicating the insider has historically sold before rallies, not declines. Her cross-ticker track record similarly shows 0.00% well-timed rate with an average 90-day return of +2.8% after sells, meaning her sells have not preceded downturns. The current transaction follows this established pattern: a substantial reduction in holdings at a stock price within recent highs, without a clear macro or company-specific catalyst evident in the fundamentals ($60.5B revenue, $1.6B net income, +8.2% YoY growth, P/E 23.57).

Triplett (Special Advisor, CI) sold 6,819 shares for $2.2M across 2 transactions on 2024-08-12.

Triplett Michael W completed 2 separate sales totaling 6,819 shares for $2,249,851.20, reducing his holdings from 39,652 to 32,833 shares (-17.2% reduction). The blended average sale price of $329.94 is $5.04 below the current price of $334.90, indicating the stock has risen modestly since the August 12 execution. The holder retained 32,833 shares post-transaction, maintaining a substantial position in Cigna at a company with $60.5B in quarterly revenue and a P/E of 23.57. Without visibility into whether these sales were scheduled (10b5-1) or discretionary, and given only the single-transaction snapshot, the activity represents a moderate reduction in exposure rather than a material liquidation event.

Evanko sells 4.8K CI shares at $345.01; price now $337.58. One prior CI sale occurred 90d after stock rose +3.1%.

Evanko Brian C sold 4,795 shares of Cigna Group for $1,654,302.81 on 2024-06-24 at $345.01, reducing his stake by -10.5% to 40,934 shares. His only prior trade at Cigna was a sale on 2023-08-02 where the stock subsequently rose +3.1% over 90 days—a poorly timed outcome—with 0 of 1 prior sells well-timed at the 90-day mark. The current price of $337.58 is -7.3% from the 52-week high of $364.08, and the stock is -7.0% over 90 days. Cigna's fundamentals show net income of $-212.0M against $57.3B in revenue, with P/E of 24.88. The transaction reflects a notable reduction in holdings but lacks a distinguishing pattern at this ticker; his cross-ticker sell track record shows 0.00% well-timed rate across all open-market history.